肺炎患者实施MRSA鼻腔拭子采样前后革兰阴性菌抗生素治疗时长的比较
该回顾性图表综述纳入240例肺炎患者(实施前后各120例),比较实施MRSA鼻腔PCR拭子前后革兰阴性菌治疗时长。实施后组中位治疗时长154.0小时 vs 实施前组176.4小时(P=0.002),人均革兰阴性菌方案费用实施后组31.36美元 vs 实施前组45.90美元(P=0.002)。降阶梯时间和静脉转口服时间两组无显著差异。
要点
- 实施MRSA鼻腔拭子后肺炎患者革兰阴性菌治疗中位时长154.0小时,短于实施前的176.4小时(P=0.002)。
- 实施后组人均革兰阴性菌方案费用31.36美元,低于实施前组的45.90美元(P=0.002)。
- 降阶梯时间(52.7 vs 54.9小时,P=0.351)和静脉转口服时间(53.0 vs 57.3小时,P=0.289)两组无显著差异。
核心结论
- MRSA鼻腔拭子作为抗菌药物管理工具与革兰阴性菌治疗总时长缩短及革兰阴性菌方案费用降低相关,为其作为抗菌药物管理工具增加了额外获益并进一步激励其使用。
研究设计与样本
- 回顾性图表综述,比较实施MRSA鼻腔拭子前后肺炎患者的革兰阴性菌治疗时长,共纳入240例患者,实施前后每组各120例。
主要发现
- 革兰阴性菌治疗中位时长实施后组154.0小时 vs 实施前组176.4小时(P=0.002)。
- 降阶梯时间实施后组52.7小时 vs 实施前组54.9小时(P=0.351),无显著差异。
- 静脉转口服治疗时间实施后组53.0小时 vs 实施前组57.3小时(P=0.289),无显著差异。
- 人均革兰阴性菌方案费用实施后组31.36美元 vs 实施前组45.90美元(P=0.002)。
临床怎么用
- 原文结论认为MRSA鼻腔拭子作为抗菌药物管理工具与革兰阴性菌治疗时长缩短和费用降低相关,并进一步激励其作为抗菌药物管理工具使用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The implementation of MRSA PCR nasal swabs has been shown to decrease the use of anti-MRSA therapies through faster antibiotic de-escalation in patients with pneumonia. While this benefit has been shown exclusively in Gram-positive therapy, swab results may lead to additional antibiotic de-escalation discussions early on, potentially providing reduced durations or de-escalations of Gram-negative therapy as well. OBJECTIVES: To determine if early de-escalation discussions prompted by MRSA swab results lead to shorter durations of Gram-negative antibiotic therapy. METHODS: A retrospective chart review was conducted to compare pneumonia duration of Gram-negative therapy pre- and post-implementation of MRSA nasal swabs. Time to de-escalation, time to conversion to enteral therapy and cost were also compared between the groups. RESULTS: Data were collected for 240 patients overall, 120 in each group. The median duration of Gram-negative therapy was 154.0 h in the post-implementation group and 176.4 h in the pre-implementation group (P = 0.002). There was no significant difference in time to de-escalation (52.7 versus 54.9 h; P = 0.351) or time to transition from IV to enteral therapy (53.0 versus 57.3 h; P = 0.289). The median cost of Gram-negative regimens per patient was less expensive in the post-implementation group ($31.36 versus $45.90; P = 0.002). CONCLUSIONS: MRSA nasal swabs as an antimicrobial stewardship tool were associated with a reduced overall duration of Gram-negative therapy and Gram-negative antibiotic regimen cost. This introduces an additional benefit of MRSA nasal swabs and further incentivizes their use as an antimicrobial stewardship tool.
引用
- Troyer BS, Shigle AJ, Kovacic Scherrer N, et al. Duration of Gram-negative antibiotic therapy in patients with pneumonia prior to and after the implementation of MRSA nasal swabs, an antimicrobial stewardship tool. J Antimicrob Chemother. 2022. PMID: 35733340. doi:10.1093/jac/dkac198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。